Teaching a Clone to Walk, One Step at a Time.
Development of broad HIV neutralizing antibodies during infection requires prolonged exposure to viral variants. A series of three studies published in this issue of Cell and a related paper in Immunity report new HIV structure-based design efforts focused on sequential boosting regimens with antigens of increasing maturation that point the way forward for an effective HIV vaccine strategy.
Departments of Pediatrics, Pathology, Microbiology, and Immunology and Vanderbilt Vaccine Center, Vanderbilt University Medical Center, Nashville, TN 37232, USA. Electronic address: james.crowe@vanderbilt.edu.
James E
JE
Crowe
D016915:AIDS Vaccines / Q000276:immunology*; D057134:Antibodies, Neutralizing / Q000276:immunology; D015483:HIV Antibodies / Q000276:immunology; D015658:HIV Infections / Q000276:immunology*; D015497:HIV-1 / Q000276:immunology; D006801:Humans
D016915:AIDS Vaccines; D057134:Antibodies, Neutralizing; D015483:HIV Antibodies